Market Cap: $211.18M
AS
AC Immune S.A.
ACIU
NASDAQ (NASDAQ Global Market)USD
Market Cap: $211.18M
AC Immune Advances Immunotherapy for Parkinson's Disease with Promising Trial Results AC Immune SA announces promising interim results from its Phase 2 VacSYn trial for ACI-7104.056, an innovative ant…
AC Immune Advances Parkinson's Disease Treatment with Promising Trial Results AC Immune SA announces encouraging interim results from its Phase 2 VacSYn trial for ACI-7104.056, an active immunotherapy…
AC Immune Advances Parkinson’s Disease Treatment with Promising Trial Results AC Immune SA (NASDAQ: ACIU) announces interim safety and efficacy results from its Phase 2 VacSYn trial, focusing on ACI-7…
AC Immune SA's Advancements in Alzheimer's Disease Research AC Immune SA, a biopharmaceutical company dedicated to neurodegenerative diseases, focuses on developing innovative therapies for Alzheimer'…
AC Immune SA Enhances Alzheimer’s Research with New Biomarker Discovery AC Immune SA, a biopharmaceutical company specializing in neurodegenerative diseases, announces a significant advancement in the…
AC Immune SA Advances Alzheimer's Disease Research with Promising Therapeutics AC Immune SA, a pioneering Swiss biotech firm focused on developing innovative therapies for neurodegenerative diseases,…